Handelsavisen
prelaunch
Companies Healthcare IINN.O
II
IINN.O NASDAQ Advanced Medical Equipment & Technology

Inspira Technologies Oxy BHN Ltd

$1,41
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
61,0M USD
P/E
EV / Rev
Div yield
Op margin
-4 713,8 %
ROE
-569,1 %
Net margin
-4 574,4 %
Debt / equity
0,00
Beta
52w range
Volume
Day range
Prev close
$0,45
Open
Next earnings
2026-10-28
Ex-dividend
TR 1Y
About

Inspira Technologies Oxy BHN Ltd designs, develops, and commercializes advanced medical equipment and technology solutions, primarily serving the healthcare services and equipment sector.

Business. Inspira Technologies Oxy BHN Ltd (IINN.O) is a healthcare company operating in the Advanced Medical Equipment & Technology industry. The firm engages in the sale of healthcare equipment and is listed on the NASDAQ exchange. Specific details regarding its operating segments, headquarters location, and geographic revenue mix are not available in the provided data.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryAdvanced Medical Equipment & Technology
ActivityHealthcare Equipment
Generated · model-assisted
Sell-side consensus
BUY1 analysts
1 buy0 hold0 sell
Avg 12m price target5,00

Analyst recommendations

1 analysts · consensus Buy
Buy1
Hold0
Sell0
12-month price target
5,00
Consensus of sell-side coverage.
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
1 analysts · indicative
Ownership
UBS Financial Services, Inc.
largest disclosed fund holder
Profitability
-569,1 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning IINN.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to IINN.O. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Inspira Technologies Oxy BHN Ltd (IINN.O) is a healthcare company operating in the Advanced Medical Equipment & Technology industry. The firm engages in the sale of healthcare equipment and is listed on the NASDAQ exchange. Specific details regarding its operating segments, headquarters location, and geographic revenue mix are not available in the provided data.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryAdvanced Medical Equipment & Technology
    ActivityHealthcare Equipment
    AI synthesis
    GENERATED

    Inspira Technologies Oxy BHN Ltd maintains a strong liquidity position, with $3.16 million in cash and equivalents, representing 59.1% of total assets. The company has no long-term debt and a current ratio of 1.56, indicating sufficient short-term liquidity to cover obligations. However, the firm reported negative operating and free cash flows of -$9.86 million and -$12.87 million, respectively, signaling ongoing operational cash burn.

    Profitability metrics are severely negative, with a net loss of $13.22 million and an operating loss of $13.62 million. Return on equity (ROE) and return on assets (ROA) are -5.69% and -2.48%, respectively, far below the industry median for advanced medical equipment firms. The company's price-to-book ratio of 8.38 and enterprise value-to-revenue ratio of 56.45 suggest a premium valuation relative to tangible asset base and revenue, despite unprofitable operations.

    The firm operates as a single-segment entity with no disclosed geographic revenue breakdown. This lack of diversification introduces concentration risk, as the company's performance is entirely dependent on its core product lines and regional demand. No material revenue concentration by geography or customer is reported in the latest filings.

    Growth prospects remain uncertain, with no revenue growth reported in the latest period. The company's operating losses and negative cash flows indicate a lack of scalable revenue generation. Analysts have assigned a mean price target of $5.00, implying a 1,000% upside from the current market price of $0.45, though this is based on a single "buy" recommendation with no supporting detail.

    Risk factors include liquidity risk from negative operating cash flows and dilution risk from potential future equity raises to fund operations. The firm has no immediate filing-based liquidity or dilution flags, but its capital structure shows no dilution in the current period (basic and diluted shares are equal). No adjustments were applied to valuation metrics, indicating clean financial reporting.

    Recent events include the publication of the latest financial snapshot, which shows continued operational losses and no material changes in capital structure. No recent filings, transcripts, or regulatory actions were identified in the available data.

    Key takeaways
    • Inspira Technologies Oxy BHN Ltd is a loss-making advanced medical equipment firm with a premium valuation despite negative cash flows and returns.
    • The company's liquidity position is strong in absolute terms but unsustainable given ongoing operational cash burn.
    • Analysts have assigned a high price target, but the recommendation is based on a single "buy" rating with no supporting detail.
    • The firm's lack of geographic or segment diversification introduces concentration risk.
    • No immediate liquidity or dilution flags are present, but future equity raises may be necessary to fund operations.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $1,41
    Market cap
    $19.5M
    Enterprise value
    $16.3M
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    8.4x
    P / Tangible book
    8.4x
    Tangible book
    $2.3M
    Net cash
    $3.2M
    Current ratio
    1.6
    Debt / equity
    0.0
    ROA
    -2.5%
    ROE
    -5.7%
    Cash conversion
    75.0%
    CapEx / revenue
    -35.6%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    0,11
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    1
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-10 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate0,11
    Revenueno estimateno estimate48,0M USD
    Operating incomeno estimateno estimate4,2M USD
    Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution1 analysts
    Strong buy0
    Buy1
    Hold0
    Sell0
    Strong sell0
    12-month price target$5,00 · Median $5,00
    Low $5,00High $5,00
    Operating income · consensus4,2M USD
    EPS surprise
    −509,1 %
    reported vs consensus · miss
    Revenue surprise
    −99,4 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$5,00
    Mean$5,00
    Median$5,00
    High$5,00
    Spot$1,41
    +254.6 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin-4 713,8 %Bottom quartile
    Net Margin-4 574,4 %Bottom quartile
    ROE-569,1 %Bottom quartile
    Capex / Rev-35,6 %Bottom quartile
    D/E0,00Above median
    Cash Conv0,75Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Return On Equity
      net_income / total_equity
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    • Ev To Revenue
      enterprise_value / revenue
    Source documents
    • Inspira Technologies Oxy BHN Ltd Market data — financials · 2026-05-28
    • Inspira Technologies Oxy BHN Ltd Market data — analyst estimates · 2026-05-28

    Ownership & reference

    Top holders

    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$0M
    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$0M

    Insider activity

    — missing data

    Short positioning

    813.5Kshares short-10.3% vs prior
    3.11days to cover
    16.7Kfails-to-deliver
    as of 2026-05-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    IINN.OCanonical
    NASDAQ · USD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    • R&D expense (YoY) (2025-12-31 vs 2024-12-31): 18.6%Derived (calculated)
    • Operating income (YoY) (2025-12-31 vs 2024-12-31): -20.9%Derived (calculated)
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): -33.8%Derived (calculated)
    • Return on assets (FY 2025-12-31): -247.5%Derived (calculated)
    • Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -5.2%Derived (calculated)
    • Current ratio (FY 2025-12-31): 1.56xDerived (calculated)
    • Net margin (FY 2025-12-31): -4,574.4%Derived (calculated)
    • Capex (YoY) (2025-12-31 vs 2024-12-31): -37.2%Derived (calculated)
    • EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 25.0%Derived (calculated)
    • Net income (YoY) (2025-12-31 vs 2024-12-31): -19.6%Derived (calculated)
    • EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 25.0%Derived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -46.3%Derived (calculated)
    • Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -38.2%Derived (calculated)
    • Gross margin (FY 2025-12-31): 0.7%Derived (calculated)
    • Return on equity (FY 2025-12-31): -569.1%Derived (calculated)
    • Net income (annual): USD -13.22MSEC XBRL filing
    • Revenue (annual): USD 289KSEC XBRL filing
    • Gross profit (annual): USD 2KSEC XBRL filing
    • Shareholders' equity (annual): USD 2.32MSEC XBRL filing
    • Total assets (annual): USD 5.34MSEC XBRL filing
    • Operating income (annual): USD -13.62MSEC XBRL filing
    • R&D expense (annual): USD 7.5MSEC XBRL filing
    • Operating cash flow (annual): USD -9.86MSEC XBRL filing
    • Current liabilities (annual): USD 2.82MSEC XBRL filing
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-07-29 22:34 UTCEVENTHa Price Listing IINN remains DEFICIENT (NASDAQ) — cure period. closed below $1.00 for 101 consecutive trading days (last close $0.3985). cure deadline 2027-01-17 (172 days remaining).
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage